Review Article

Revolutionizing Cancer Treatment: Harnessing the Power of Biomarkers to Improve Patient Outcomes

Donald C. Moore,(1) PharmD, BCPS, BCOP, DPLA, FCCP, and Andrew S. Guinigundo,(2) MSN, RN, CNP, ANP-BC

From (1)Department of Pharmacy, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina; (2)Cincinnati Cancer Advisors, Cincinnati, Ohio

Authors’ disclosures of conflicts of interest are found at the end of this article.

Correspondence to: Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP, Levine Cancer Institute, 1021 Morehead Medical Drive, Charlotte, NC 28204. E-mail: donald.moore1@atriumhealth.org

ABSTRACT

There has been an increasing number of approvals for targeted therapies and immunotherapies in oncology in the past decade. This has changed the treatment paradigm for many solid tumors and hematologic malignancies, and therefore the outcomes of patients with cancer. Advanced practitioners should be up to date with advances in cancer biomarker testing and its implications for the use of targeted therapy and immunotherapy to integrate this information into clinical decision-making.

Advances in Biomarker-Driven Therapy: Implications for Advanced Practitioners
Revolutionizing Cancer Treatment: Harnessing the Power of Biomarkers to Improve Patient Outcomes
Biomarker-Driven Oncology Clinical Trials: Novel Designs in the Era of Precision Medicine
The Role of Biomarkers in Guiding Clinical Decision-Making in Oncology
The Advanced Practitioner’s Role in the Rapidly Evolving Landscape of Precision Medicine

For access to the full length article, please sign in.